ClinicalTrials.gg
RecruitingNCT06424977BTSEEUpdated Nov 16, 2026

Biomarker Targeted Stimulation for Epileptiform Events

An interventional study of Biomarker Targeted Stimulation (BTS) in Epilepsy, sponsored by Cadence Neuroscience. Recruiting at 4 sites in United States. Open to male participants aged 7 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Cadence Neuroscience · Not applicable, Interventional, and Treatment

How we know

Updated Nov 16, 2026Now RecruitingFirst site in United States+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
7 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 793 studies in Epilepsy with a site in United States — 159 open to participants now, 194 under way, 17 of them phase 3. Epilepsy · United States.

Planned enrollment
290th of 588
40 · median 40
Started
2026
with 32 others
No phase
222 of 793
79 open now
Primary completion
2028-05
later than 122 of 191 live
Registered
707th of 793
by date

Among the 793 studies in Epilepsy with a site in United States, this one is the 290th largest by planned enrollment of the 588 interventional ones that give a count, is one of 33 that started in 2026, is one of 222 with no phase, reaches primary completion later than 122 of the 191 other live ones, and was the 707th registered.

Epilepsy

1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

Browse Epilepsy studies →

Open to participants now

159 of the 793 studies in Epilepsy with a site in United States are open now. Recruiting first, the newest first:

153 more — sign in →

All 159 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.

This study: 7 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 793 studies in Epilepsy with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, prospective, controlled study designed to evaluate treatment with the BTS System.

03

Conditions studied

  • Epilepsy

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 9, 2026. See what changed

Ages eligible
7 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is greater than or equal to 7 years of age.
  2. Subject has focal onset seizures.
  3. Subject has failed treatment with a minimum of two AED's used in typical therapeutic dosages.
  4. Subject has seizures that are distinct, stereotypical events that can be reliably counted by the patient or caregiver.
  5. Subject can reasonably be expected to maintain a seizure diary and the BTS System alone, or with the assistance of a competent individual.
  6. For one month prior to enrollment, subject's anti-epileptic medication dosages and ketogenic diet (as applicable) have been stable (other than acute, intermittent use of benzodiazepines) and subject has had at least three primary, disabling seizures per month, on average. Seizures must be separated by a minimum of eight hours not to be considered part of a cluster. A cluster, for the purpose of this criterion, shall be considered a single seizure.
  7. Subject is able to complete regular office visits and telephone appointments in accordance with the study protocol requirements.
  8. A female subject of childbearing age must have a negative serum pregnancy test within two weeks prior to implant of the INSR, and, if sexually active, must be using a reliable form of , be surgically sterile, or be at least two years .
  9. Subject has been informed of their eligibility for resective surgery as a potential alternative to the study, if such surgery is a reasonable option.
  10. Subject has had a brain MRI epilepsy evaluation within the past two years.
  11. Subject's anatomy will permit implantation of the INSR within 20 mm of the skin surface.

Exclusion criteria

Exclusion Criteria:

  1. Subject has a history of substance abuse within the preceding two years.
  2. Subject participated in another drug or device trial that may confound study results within the preceding 30 days.
  3. Subject is implanted with pacemaker, implantable cardiac defibrillator, cardiac management product, or a medical device that interferes with the BTS System or with which the BTS System interferes. Patients with a vagus nerve stimulator (VNS) implanted may be enrolled, provided their VNS remains off while the BTS System is implanted.
  4. Subject has anatomy that may interfere with electrode placement.
  5. Subject is on anticoagulants and is unable to discontinue them perisurgically, as required by the neurosurgeon or Investigator.
  6. Subject has significant dysfunction from medical conditions or medications (including, particularly, aspirin or sodium valproate). If platelet dysfunction is suspected, subject can be enrolled only if a hematologist, the Investigator, and the neurosurgeon judge it to be advisable.
  7. Subject has been diagnosed with psychogenic or non-epileptic seizures that cannot be distinguished from their epileptogenic events.
  8. Subject is ineligible for cranial surgery or has medical and/or neurologically unstable condition (e.g brain tumor, multiple sclerosis, dementia, or intracranial vascular lesion).
  9. Subject has been diagnosed with active psychosis, major depression, or suicidal ideation in the preceding 6 months.
  10. Subject has primary generalized seizures.
  11. Subject has experienced unprovoked convulsive status epilepticus in the preceding year, defined as:

    1. The active part of a tonic-clonic seizure lasts 5 minutes or longer, or
    2. Repeated tonic-clonic seizures without recovering consciousness for a period of longer than 5 minutes
  12. Subject, in the opinion of the Investigator, would be a poor study candidate.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Treatment

    Device: Biomarker Targeted Stimulation (BTS)

Interventions

  • DeviceBiomarker Targeted Stimulation (BTS)

    Using continuous stimulation to target multiple network nodes, Biomarker Targeted Stimulation (BTS) is intended to suppress abnormal interictal activity, as determined by biomarkers including interictal epileptiform discharges (IED) and high frequency oscillations (HFO), with the intention to reduce brain hyperexcitability, thereby limiting seizure occurrence.

06

What researchers measure

Primary outcomes

  1. Adverse event rate

    Determine adverse event rate, including adverse device effects and serious adverse events

    Time frame: Intervals through 7, 12, and 24 months post-implant

Secondary outcomes

  1. Seizure frequency

    Using seizure diaries, calculate disabling seizure frequency, normalized to months, compared to baseline.

    Time frame: Intervals calculated at 4 to 7 months and through 12 and 24 months post-implant.

  2. Neurocognitive testing

    Neurocognitive tests, using the NIH Toolbox, including the Flanker Inhibitory Control and Attention Test, Picture Sequence Memory Test, and Picture Vocabulary Test, compared to baseline.

    Time frame: Evaluated at 7 months, 12 months, and 24 months post-implant.

  3. Depression testing

    Patient reported depression evaluation using Child Depression Inventory (CDI) or Beck Depression Inventory (BDI) (depending on age), compared to baseline.

    Time frame: Evaluated at 7 months, 12 months, and 24 months post-implant.

  4. Anxiety testing

    Patient reported anxiety evaluation using Revised Children's Manifest Anxiety Scale (RCMAS-2) or Beck Anxiety Inventory (depending on age), compared to baseline.

    Time frame: Evaluated at 7 months, 12 months, and 24 months post-implant.

  5. Quality of life testing

    Patient reported quality of life evaluation using Quality of Life in Childhood Epilepsy Questionnaire (QOLCE-55), Quality of Life in Epilepsy Inventory for Adolescents (QOLIE-AD-48), or Quality of Life in Epilepsy (QOLIE-31) (depending on age), compared to baseline.

    Time frame: Evaluated at 7 months, 12 months, and 24 months post-implant.

  6. Sleep testing

    Patient reported sleep evaluation using Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD) or Epworth Sleepiness Scale (ESS) (depending on age), compared to baseline.

    Time frame: Evaluated at 7 months, 12 months, and 24 months post-implant.

  7. Seizure severity testing

    Patient reported seizure severity evaluation using Liverpool Seizure Severity Scale 2.0 (LSSS 2.0), compared to baseline.

    Time frame: Evaluated at 7 months, 12 months, and 24 months post-implant.

  8. Caregiver burden testing

    Caregiver reported burden evaluation using Caregiver Burden Inventory (CBI), compared to baseline.

    Time frame: Evaluated at 7 months, 12 months, and 24 months post-implant.

  9. Suicidality risk testing

    Tool used to assess the severity and immediacy of suicide risk through a series of plain-language questions, compared to baseline.

    Time frame: Evaluated at 7 months, 12 months, and 24 months post-implant.

07

Study locations

4 of 4 sites recruiting
08

References and documents

Publications

  • Lundstrom BN, Worrell GA, Stead M, Van Gompel JJ. Chronic subthreshold cortical stimulation: a therapeutic and potentially restorative therapy for focal epilepsy. Expert Rev Neurother. 2017 Jul;17(7):661-666. doi: 10.1080/14737175.2017.1331129. Epub 2017 May 25. PubMed 28532252 ↗
  • Kerezoudis P, Grewal SS, Stead M, Lundstrom BN, Britton JW, Shin C, Cascino GD, Brinkmann BH, Worrell GA, Van Gompel JJ. Chronic subthreshold cortical stimulation for adult drug-resistant focal epilepsy: safety, feasibility, and technique. J Neurosurg. 2018 Aug;129(2):533-543. doi: 10.3171/2017.5.JNS163134. Epub 2017 Oct 20. PubMed 29053073 ↗
  • Lundstrom BN, Gompel JV, Khadjevand F, Worrell G, Stead M. Chronic subthreshold cortical stimulation and stimulation-related EEG biomarkers for focal epilepsy. Brain Commun. 2019;1(1):fcz010. doi: 10.1093/braincomms/fcz010. Epub 2019 Sep 6. PubMed 31667473 ↗
  • Starnes K, Miller K, Wong-Kisiel L, Lundstrom BN. A Review of Neurostimulation for Epilepsy in Pediatrics. Brain Sci. 2019 Oct 18;9(10):283. doi: 10.3390/brainsci9100283. PubMed 31635298 ↗
  • Alcala-Zermeno JL, Gregg NM, Van Gompel JJ, Stead M, Worrell GA, Lundstrom BN. Cortical and thalamic electrode implant followed by temporary continuous subthreshold stimulation yields long-term seizure freedom: A case report. Epilepsy Behav Rep. 2020 Sep 2;14:100390. doi: 10.1016/j.ebr.2020.100390. eCollection 2020. PubMed 32995742 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for May 2028, 18 months later.

Of 360 interventional studies with no phase under Epilepsy, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 77. This study's planned 18 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: start Sep 2026 → Nov 2026, primary completion Sep 2028 → May 2028 and completion Feb 2030 → Nov 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2024
First posted
May 22, 2024
StartEst.
Nov 1, 2026was Sep 2026
Primary completionEst.
May 1, 2028was Sep 2028
CompletionEst.
Nov 1, 2030was Feb 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 12, 2026
Sites
4 sites added — first site in United States
Show 4 added (4 United States)
  • Mayo Clinic · Rochester, United States
  • Lucile Packard Children's Hospital Stanford · Palo Alto, United States
  • Cook Children's Medical Center · Fort Worth, United States
  • Seattle Children's Hospital · Seattle, United States
across 2 updates, Nov 12, 2026 – Nov 16, 2026
Start date
Sep 1, 2026→Nov 1, 2026
Oct 27, 2026
Primary completion
Sep 1, 2028→May 1, 2028
Oct 27, 2026
Study completion
Feb 14, 2030→Nov 1, 2030
Oct 27, 2026
Eligibility
1 exclusion criterion edited, 7 added, 1 removed
What changed in the criteria
Exclusion criteria
  • EditedSubject is implanted with pacemaker, implantable cardiac defibrillator, cardiac management product, or a medical device that interferes with the BTS System or with which the BTS System interferes. Patients with a vagus nerve stimulator (VNS) implanted may be enrolled, provided their clinical status has been stable for at least one month prior to enrollment at their current stimulation parameter settingsVNS remains off while the BTS System is implanted.
  • RemovedSubject is ineligible for cranial surgery.
  • AddedSubject is ineligible for cranial surgery or has medical and/or neurologically unstable condition (e.g brain tumor, multiple sclerosis, dementia, or intracranial vascular lesion).
  • AddedSubject has been diagnosed with active psychosis, major depression, or suicidal ideation in the preceding 6 months.
  • AddedSubject has primary generalized seizures.
  • AddedSubject has experienced unprovoked convulsive status epilepticus in the preceding year, defined as:
  • AddedThe active part of a tonic-clonic seizure lasts 5 minutes or longer, or
  • AddedRepeated tonic-clonic seizures without recovering consciousness for a period of longer than 5 minutes
  • AddedSubject, in the opinion of the Investigator, would be a poor study candidate.
Nov 9, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • AddedSuicidality risk testingTime frame: Evaluated at 7 months, 12 months, and 24 months post-implant.
Nov 9, 2026
Show all 4 updates
  1. Nov 16, 2026
    3 sites added
    Show 3 added (3 United States)
    • Lucile Packard Children's Hospital Stanford · Palo Alto, United States
    • Cook Children's Medical Center · Fort Worth, United States
    • Seattle Children's Hospital · Seattle, United States
  2. Nov 12, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Mayo Clinic · Rochester, United States
    + 1 other change: verification date
  3. Nov 9, 2026
    Eligibility 1 exclusion criterion edited, 7 added, 1 removed
    What changed in the criteria
    Exclusion criteria
    • EditedSubject is implanted with pacemaker, implantable cardiac defibrillator, cardiac management product, or a medical device that interferes with the BTS System or with which the BTS System interferes. Patients with a vagus nerve stimulator (VNS) implanted may be enrolled, provided their clinical status has been stable for at least one month prior to enrollment at their current stimulation parameter settingsVNS remains off while the BTS System is implanted.
    • RemovedSubject is ineligible for cranial surgery.
    • AddedSubject is ineligible for cranial surgery or has medical and/or neurologically unstable condition (e.g brain tumor, multiple sclerosis, dementia, or intracranial vascular lesion).
    • AddedSubject has been diagnosed with active psychosis, major depression, or suicidal ideation in the preceding 6 months.
    • AddedSubject has primary generalized seizures.
    • AddedSubject has experienced unprovoked convulsive status epilepticus in the preceding year, defined as:
    • AddedThe active part of a tonic-clonic seizure lasts 5 minutes or longer, or
    • AddedRepeated tonic-clonic seizures without recovering consciousness for a period of longer than 5 minutes
    • AddedSubject, in the opinion of the Investigator, would be a poor study candidate.
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedSuicidality risk testingTime frame: Evaluated at 7 months, 12 months, and 24 months post-implant.
  4. Oct 27, 2026
    Start date Sep 1, 2026→Nov 1, 2026
    Primary completion Sep 1, 2028→May 1, 2028
    Study completion Feb 14, 2030→Nov 1, 2030
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06424977
Lead sponsor
Cadence Neuroscience
Responsible party
Sponsor
First posted
May 22, 2024
Start date
Nov 1, 2026 (estimated)
Primary completion
May 1, 2028 (estimated)
Completion
Nov 1, 2030 (estimated)
Last update
Nov 16, 2026

Study contacts

David Himes, BSEE
Contact
dhimes@cadenceneuro.com
425-679-9505

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion